prompt1 : extract information from  breast pathology report. List the histological classification, i.e. type of cancer or DCIS, subtype, description of any necrosis, any mention of tumor infiltrating lymphocytes,  histological grade, nuclear grade,  lymphovascular invasion, calcification, receptor status, IHC and any other ancillary testing results.  List out and expand the main points.
prompt2 : The report is - Subtype LumA, DIAGNOSIS. (A) SENTINEL LYMPH NODE #1, LEFT AXILLA, BIOPSY: One lymph node, no tumor present (0/1). Cytokeratin stain shows no evidence of metastatic carcinoma. (B) SENTINEL LYMPH NODE #2, LEFT AXILLA, BIOPSY: One lymph node, no tumor present (0/1). Cytokeratin stain shows no evidence of metastatic carcinoma. (C) LEFT BREAST, SEGMENTAL MASTECTOMY: INVASIVE DUCTAL CARCINOMA OF BREAST, MODIFIED BLACK'S NUCLEAR GRADE 1 (WELL. DIFFERENTIATED). (SEE COMMENT). INVASIVE CARCINOMA MEASURES 1.6 X 1.6 X 1.2 CM GROSSLY. No lymphatic/vascular invasion identified. FOCAL INTRADUCTAL CARCINOMA (DCIS), MODIFIED BLACK'S NUCLEAR GRADE 2 (INTERMEDIATE GRADE), THE. MICROPAPILLARY AND CRIBRIFORM TYPES WITH NECROSIS, COMPRISING LESS THAN 5% OF. TUMOR. INVASIVE CARCINOMA ABUTS BUT NOT INVADES INTO THE POSTIERIOR SKELETAL MUSCLE. Surgical margins are free of tumor. INVASIVE CARCINOMA IS 1.5 MM TO THE CLOSEST POSTERIOR MARGIN, AND 5.0 MM TO THE. INFERIOR MARGIN. Focal atypical ductal hyperplasia. Biopsy site changes. Proliferative fibrocystic change. (D) NEW DEEP MARGIN, LEFT BREAST, EXCISION: Benign skeletal muscle, no tumor present. Entire report and diagnosis completed by. COMMENT. Tumor markers have been performed on prior core biopsy i. ). FISH study for HER2/neu gene amplification will be. ordered. Results will be issued in an addendum. The periphery of the invasive carcinoma shows neuroendocrine features. Although the tumor is negative for the neuroendocrine. markers (chromogranin and synaptophysin) on the core biopsy material, these markers will be repeated and report in an. addendum. CROSS DESCRIPTION. (A) SLN #1, LEFT AXILLA, BLUE NO, IN VIVO 147, EX VIVO 200 - One lymph node is identified (2.2 x 2.0 x 1.0 cm). Segially. sectioned. Totally submitted in A1-A3. 1. (B) SLN #2, LEFT AXILLA, BLUE NO, IN VIVO 19, EX VIVO 20 - One lymph node is identified (0.8 x 0.4 x 0.3 cm). Totally. submitted in B. (C) LEFT BREAST SEGMENTAL MASTECTOMY - A specimen of segmental mastectomy (6.0 x 4.5 x 3.0 cm). The specimen is. oriented with short stitch at superior aspect and with long stitch at lateral aspect. The specimen is serially sliced from medial to. lateral. aspect. (seven slices). A tumor measuring 1.6 x 1.6 x 1.2 cm isidentified,which is .2cm to the closes posterior margin. The tumor appears to be ill-defined, tan-pink-yellow and firm. INK CODE: Anterior - yellow; posterior - black; superior - blue; inferior - green; medial - orange; lateral - red. SECTION CODE: C1, C2, medial perpendicular margin; C3, C4, sections from slice 2 (C3, tumor and posterior and. inferior. margin;. C4, posterior and superior margin); C5-C7, sections from slices #3 (C5, tumor and posterior and inferior margin;. C6. posterior and superior margin; C7, anterior margin); C8, tissue adjacent to tumor from slice 4; C9, lateral perpendicular margin. (D). NEW. DEEP. MARGIN, LEFT BREAST - Received is muscle tissue (4.0 x 2.5 x 0.6 cm) with clips marked as true margin. The. true margin is inked black. The specimen is serially sectioned and totally submitted in D1-D5. CLINICAL HISTORY. Left breast cancer. SNOMED CODES. T-04050, M-85003, M-85002, T-C4714, M-00110. "Some tests reported here may have been developed and performance characteristics determined by. These tests have not been specifically cleared or approved by the U.S. Food and Drug Administration.". Released by: \. Start of ADDENDUM. ADDENDUM. Addendum completed bv \. COMMENT. This addendum is issued to give immunohistochemical results. Invasive carcinoma is negative for neuroendocrine markers, synaptophysin, chromogranin and CD56. The Ki-67 proliferation. index is low (10%). Heleased by: Start of ADDENDUM #2. Addendum # 2. SPECIMEN SOURCE. Left breast. SUMMARY. Tissue section of the invasive carcinoma. C5 was evaluated for HER-2/neu gene amplification by interphase. fluorescence in situ hybridization technique using the PathVysion HER-2/neu DNA Probe Kit (LSI HER-2/neu. SpectrumOrange/CEP17 SpectrumGreen). Slide adequacy is satisfactory. Sixty tumor nuclei were counted and showed an average of 2.23 copies of LSI HER-2/neu gene. per nucleus and an average of 1.93 copies of CEP17 per nucleus. Negative and positive controls (established by. with this batch are appropriate. Two representative images have been archived. INTERPRETATION. The tumor cells demonstrated no amplification of the HER-2/neu gene copy levels (HER-2/neu: CEP17 signal ratio: 1.16 ). Normal levels (HER-2/neu: CEP17 signal ratio) <2.0. NOTES. The LSI HER-2/neu probe is specific for the HER-2/neu gene Locus (17q 11.2-q12) and the CEP 17 DNA probe is specific for the. alpha satellite DNA sequence at the centromeric region of Chromosome 17 (17 p11.1 -q11.2). This test has been cleared and approved for specific uses by the U.S. Food and Drug Administration. Its system is operating. within the performance specifications stated in the product insert. Released by:

expanded version (tokens=1768) : 
 The breast pathology report indicates the following:

- Histological classification: Invasive ductal carcinoma of the breast with focal intraductal carcinoma (DCIS)
- Subtype: LumA
- Nuclear grade: Modified Black's nuclear grade 1 (well-differentiated)
- Necrosis: Micropapillary and cribriform types with necrosis (comprising <5% of tumor) in the DCIS component
- Tumor infiltrating lymphocytes: Not mentioned
- Lymphovascular invasion: None identified
- Calcification: Not mentioned
- Receptor status: Invasive carcinoma is negative for neuroendocrine markers (chromogranin, synaptophysin, and CD56), but hormone receptor subtype and HER2 status are not provided in the main report
- Ancillary testing: FISH study for HER2/neu gene amplification will be ordered and a Ki-67 proliferation index of 10% was reported in an addendum.

In addition, the report describes the size and location of the tumor, along with surgical margins and biopsy site changes. The lymph nodes in the left axilla were negative for tumor. The report also includes descriptions of the specimens submitted, along with their orientation and sectioning.

prompt : Please generate a succinct report in 75 words from the above information. Exclude any filler words or sentences. If something is not mentioned or specified, exclude it from the report. Low verbosity.

final output (tokens=1940) : 
 The pathology report showed invasive ductal carcinoma of the breast with a focal intraductal carcinoma (DCIS) and a subtype of LumA. The tumor had modified Black's nuclear grade 1 and no lymphovascular invasion. The DCIS component had micropapillary and cribriform types with necrosis comprising less than 5% of the tumor. No tumor infiltrating lymphocytes were reported, but the receptor status was negative for neuroendocrine markers. Further testing for HER2/neu gene amplification will be done by FISH study. The Ki-67 proliferation index was at 10%.

